Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist.
The role of histamine and its receptors in basal ganglia neurocircuitry was assessed in apomorphine-induced turning behavior. Rats with unilateral 6-hydroxydopamine lesions of the substantia nigra pars compacta and medial forebrain bundle were administered histaminergic agents, and apomorphine-induced turning behavior was tested on Days 7 and 14 post-lesion. Compared with saline-treated rats, histidine (500 mg/kg, i.p.), a precursor of histamine, increased turning behavior (p<0.05), while alpha-fluoromethylhistidine (alpha-FMH, 25 microg, i.c.v.), an irreversible inhibitor of histidine decarboxylase, decreased turning behavior (p<0.05) but only on Day 14 post-lesion. Both the histamine H(1) receptor antagonist pyrilamine (10 and 50 microg, i.c.v.) and the H(2) receptor antagonist cimetidine (10 and 50 microg, i.c.v.) significantly decreased turning behavior on Days 7 and 14 post-lesion. The histamine H(3) receptor agonist immepip (10 microg, i.c.v.) decreased turning behavior (p<0.05) on Day 14 post-lesion. The present findings indicate the complex interactions of histamine on basal ganglia function.
Liu
Chun-Qing
CQ
Department of Neurobiology, Institute of Neuroscience, Zhejiang University, School of Medicine, Hangzhou, 310058, China.
Hu
Dan-Na
DN
Liu
Fu-Xin
FX
Chen
Zhong
Z
Luo
Jian-Hong
JH
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology*; D001479:Basal Ganglia / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D017442:Histamine Agonists / Q000494:pharmacology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006639:Histidine / Q000494:pharmacology; D006640:Histidine Decarboxylase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007093:Imidazoles / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D008762:Methylhistidines / Q000008:administration & dosage / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity*; D010880:Piperidines / Q000494:pharmacology; D011738:Pyrilamine / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013239:Stereotyped Behavior / Q000187:drug effects*; D013565:Sympatholytics / Q000633:toxicity*; D013569:Synapses / Q000187:drug effects; D013890:Thiourea / Q000031:analogs & derivatives / Q000494:pharmacology
D004791:Enzyme Inhibitors; D017442:Histamine Agonists; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D007093:Imidazoles; D008762:Methylhistidines; D009292:Narcotic Antagonists; D010880:Piperidines; D013565:Sympatholytics; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; D006639:Histidine; C028309:alpha-fluoromethylhistidine; D016627:Oxidopamine; D006640:Histidine Decarboxylase; D013890:Thiourea; D011738:Pyrilamine; D001058:Apomorphine; C086108:clobenpropit